Silver Linings of Post-Pandemic Trial Disruption.
- Published in:
- Applied Clinical Trials, 2020, v. 29, n. 9, p. 30
- By:
- Publication type:
- Article
Works matching IS 10648542 AND DT 2020 AND VI 29 AND IP 9
Results: 17
1
2
Integration of Point-of-Care Devices in Clinical Trials: A look at the future of clinical trial laboratory testing amid the emerging use of new devices at the point of care.
- Published in:
- Applied Clinical Trials, 2020, v. 29, n. 9, p. 28
- By:
- Publication type:
- Article
3
eCOA: A New Model for Patient-Reported Outcomes.
- Published in:
- Applied Clinical Trials, 2020, v. 29, n. 9, p. 22
- By:
- Publication type:
- Article
4
Small Biopharma and CROs: Seeking Stronger Synergies: Stakes are high for emerging biopharmaceutical companies to get their relationships with CRO partners right from the outset.
- Published in:
- Applied Clinical Trials, 2020, v. 29, n. 9, p. 16
- By:
- Publication type:
- Article
5
The Rise of FSP Outsourcing in Drug Development: Industry experts share their thoughts on the evolution of the functional service provider model, as demand for flexible resourcing grows.
- Published in:
- Applied Clinical Trials, 2020, v. 29, n. 9, p. 24
- By:
- Publication type:
- Article
6
Combating the 'Talent Wars' in Biopharma: Competency-based and other creative approaches are needed to address the battle for talent in the clinical research workforce.
- Published in:
- Applied Clinical Trials, 2020, v. 29, n. 9, p. 19
- By:
- Publication type:
- Article
7
Trial Collaboration Without Barriers: Investigator-facing SaaS platform provides shared benefits for sites and sponsors.
- Published in:
- Applied Clinical Trials, 2020, v. 29, n. 9, p. 14
- Publication type:
- Article
8
PAREXEL AND PFIZER ENTER NEXT PHASE OF PARTNERSHIP.
- Published in:
- Applied Clinical Trials, 2020, v. 29, n. 9, p. 13
- Publication type:
- Article
9
EU MAKES MORE VACCINE DEALS AS QUESTIONS MOUNT OVER TERMS.
- Published in:
- Applied Clinical Trials, 2020, v. 29, n. 9, p. 6
- By:
- Publication type:
- Article
10
EU PLANNING TO RESPOND TO DRUG INNOVATION WITH SMARTER REGULATION BY 2025.
- Published in:
- Applied Clinical Trials, 2020, v. 29, n. 9, p. 5
- By:
- Publication type:
- Article
11
INNOVATIVE CLINICAL TRIAL DESIGNS EMERGE FROM PANDEMIC.
- Published in:
- Applied Clinical Trials, 2020, v. 29, n. 9, p. 4
- By:
- Publication type:
- Article
12
FDA MAY DELAY APPROVAL OF DRUGS WHERE NECESSARY INSPECTION IS NOT FEASIBLE.
- Published in:
- Applied Clinical Trials, 2020, v. 29, n. 9, p. 13
- By:
- Publication type:
- Article
13
Trial Innovation Beyond the COVID-19 Pandemic.
- Published in:
- Applied Clinical Trials, 2020, v. 29, n. 9, p. 2
- By:
- Publication type:
- Article
14
DEBATE ACCELERATES OVER WHO GETS COVID VACCINE FIRST.
- Published in:
- Applied Clinical Trials, 2020, v. 29, n. 9, p. 12
- By:
- Publication type:
- Article
15
APPLYING PRE-PANDEMIC BENCHMARKS TO ASSESS FUTURE SPEED STRATEGIES.
- Published in:
- Applied Clinical Trials, 2020, v. 29, n. 9, p. 10
- By:
- Publication type:
- Article
16
FDA'S 'GOLD STANDARD' CRITICAL FOR BIOPHARMA R&D.
- Published in:
- Applied Clinical Trials, 2020, v. 29, n. 9, p. 9
- By:
- Publication type:
- Article
17
DECENTRALIZED TRIALS: OPENING NEW OPPORTUNITIES IN CLINICAL RESEARCH.
- Published in:
- 2020
- By:
- Publication type:
- Interview